Shots:

• Samsung Biologics and AstraZeneca had decided to suspend long-running research and development activities by a jointly-owned subsidiary- Archigen Biotech- which was solely engaged in the development of SAIT101 (biosimilar- rituximab)
• Samsung halted the P-III study of SAIT101 in Oct’2012 and resumed it in 2014 via Archigen. The P-III study similar therapeutic effect to Rituxan in 315 FL patients with ORR (66.3% vs 70.6%)
• The companies decided to stop commercializing SAIT101 and take a step for liquidation of Archigen as the product lacks commercial viability

 ­ Ref: Centerforbiosimilars- Korean Biomed  | Image: New Europe